Saba Salahuddin
Internal Medicine · Myrtle Beach, SCNPI 1821595042
Payments from drug & device makers
Across 215 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$593
- AbbVie$466
- Amgen$276
- Novartis$182
- AstraZeneca$174
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$162
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,599100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $593 |
| AbbVie | 51 | $466 |
| Amgen | 22 | $276 |
| Novartis | 11 | $182 |
| AstraZeneca | 12 | $174 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| Daiichi Sankyo Inc. | 7 | $155 |
| UCB, Inc. | 7 | $153 |
| Otsuka America Pharmaceutical, Inc. | 7 | $143 |
| Pfizer | 8 | $128 |
| Sumitomo Pharma America, Inc. | 5 | $127 |
| GSK | 7 | $118 |
| Calliditas Therapeutics US Inc. | 1 | $113 |
| Abbott | 5 | $100 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Johnson & Johnson | 3 | $51 |
| Madrigal Pharmaceuticals | 1 | $44 |
| Mylan Specialty L.p. | 2 | $41 |
| Lilly USA, LLC | 3 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Radius Health, Inc. | 2 | $38 |
| Averitas Pharma Inc. | 1 | $35 |
| Recor Medical Inc | 1 | $34 |
| Bayer | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Acadia Pharmaceuticals Inc | 1 | $30 |
| Recordati_rare_diseases_inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Boston Scientific | 1 | $20 |
| Biogen | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$113
How this compares
$3,599 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $172,597 |
| Repatha SureclickEvolocumab | 61 | $63,123 |
| EliquisApixaban | 38 | $45,564 |
| JardianceEmpagliflozin | 35 | $41,391 |
| FarxigaDapagliflozin Propanediol | 24 | $33,857 |
| XareltoRivaroxaban | 27 | $31,103 |
| TrulicityDulaglutide | 29 | $30,717 |
| JanuviaSitagliptin Phosphate | 32 | $26,287 |
| RybelsusSemaglutide | 17 | $19,632 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,490 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,205 |
| LinzessLinaclotide | 12 | $8,323 |
| Atorvastatin Calcium | 881 | $8,131 |
| Lidocaine | 12 | $7,304 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $6,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $593 | $192,229146 claims |
| PfizerEliquis | $128 | $45,56438 claims |
| Boehringer IngelheimJardiance | $19 | $41,39135 claims |
| AstraZenecaFarxiga | $174 | $33,85724 claims |
| Johnson & JohnsonXarelto | $51 | $31,10327 claims |
| Lilly USA, LLCTrulicity | $40 | $30,71729 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $118 | $22,69544 claims |
| AbbVieLinzess, Synthroid | $466 | $14,76197 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Myrtle Beach
- Edward Botse-BaidooMyrtle Beach$90K
- James IserniaMyrtle Beach$69K
- Sarah AllenMyrtle Beach$17K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.